German Breast GroupDec 6, 2023
Germline mutation status of BRCA1/2 as biomarker: Higher pCR rates observed in mutations carriers in all arms. Mutation carriers and non-carriers benefitted most from weekly nab-paclitaxel.
Analysis from GeparX-trial presented at #SABCS23 #breastcancer
Erika Hamilton, MDDec 4, 2022

I’m registered to attend #BWSS at #SABCS23 on December 5th! The Black Wo(Men) Speak Symposium, preceding San Antonio Breast, highlights the urgent need for greater diversity in clinical trials. #BWSS #MBCA

It's not too late! Register now at http://mbca.me/bws

Black Wo(Men) Speak - Metastatic Breast Cancer Alliance

Metastatic Breast Cancer Alliance